EP Patent

EP1914240B1 — EML4-ALK fusion gene

Assigned to Astellas Pharma Inc · Expires 2009-12-02 · 16y expired

What this patent protects

Patent listed against alectinib-hydrochloride.

Drugs covered by this patent

Patent Metadata

Patent number
EP1914240B1
Jurisdiction
EP
Classification
Expires
2009-12-02
Drug substance claim
No
Drug product claim
No
Assignee
Astellas Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.